| Antiprogestogen | |
|---|---|
| Drug class | |
 Mifepristone, an antiprogestogen that is used to induce medical abortions. | |
| Class identifiers | |
| Synonyms | Antiprogestins; Progesterone antagonists; Progesterone blockers |
| Use | Medical abortion, emergency contraception, uterine fibroids |
| ATC code | G03XB |
| Biological target | Progesterone receptor |
| Chemical class | Steroidal |
| Legal status | |
| In Wikidata | |
Antiprogestogens, or antiprogestins, also known as progesterone antagonists or progesterone blockers, are a class of drugs which prevent progestogens like progesterone from mediating their biological effects in the body. These drugs competitively inhibit progestin at progesterone receptors. They act by blocking the progesterone receptor (PR)and/or inhibiting or suppressing progestogen production. Antiprogestogens are one of three types of sex hormone antagonists, the others being antiestrogens and antiandrogens.[1]
Antiprogestogens are used as abortifacients and emergency contraceptives and in the treatment of uterine fibroids. They are also being studied in the treatment of breast cancer. Examples of antiprogestogens include the progesterone receptor weak partial agonist mifepristone, the selective progesterone receptor modulator (SPRM) ulipristal acetate, and the silent antagonist aglepristone.[2][3] For medical abortion, mifepristone is combined with a prostaglandin (e.g., gemeprost). Ulipristal is used as a form of emergency contraception. [4]
Several hundred antiprogestogens have been developed, but only three, mifepristone, lilopristone, and onapristone, have been given to humans, and of these, only mifepristone has been approved and introduced for clinical use.[5]
Progestins, including progesterone are important for the body to prepare the uterus for implantation of fertilized egg during the luteal phase of the menstrual cycle and, if fertilization, implantation, and other events necessary for pregnancy occur, increased progestin (i.e. progesterone) levels are heavily involved in maintaining the pregnancy. Blocking the effects of progestins, such as progesterone, is associated with anti-gestational events. [6]
See also
References
- ^ Judi Lindsley Nath (2006). Using Medical Terminology: A Practical Approach. Lippincott Williams & Wilkins. pp. 977–. ISBN 978-0-7817-4868-1.
- ^ Spitz, IM. (Oct 2006). "Progesterone receptor antagonists". Curr Opin Investig Drugs. 7 (10): 882–90. PMID 17086932.
- ^ Tang, OS.; Ho, PC. (Dec 2006). "Clinical applications of mifepristone". Gynecol Endocrinol. 22 (12): 655–9. doi:10.1080/09513590601005946. PMID 17162706. S2CID 23295715.
- ^ Le, Tao; Bhushan, Vikas; Qiu, Connie; Chalise, Anup; Kaparaliotis, Panagiotis (2023). First Aid. McGraw Hill.
- ^ Thomas H. Bourne; George Condous (17 October 2006). Handbook of Early Pregnancy Care. CRC Press. pp. 41–. ISBN 978-0-203-01621-3.
- ^ Le, Tao; Bhushan, Vikas; Qiu, Connie; Chalise, Anup; Kaparaliotis, Panagiotis (2023). First Aid. McGraw Hill.
External links
Media related to Antiprogestogens at Wikimedia Commons- Antiprogestin entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 2 November 2023, at 16:20